Outset Medical (NASDAQ:OM) CEO Sells $60,385.28 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 11,794 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $60,385.28. Following the sale, the chief executive officer owned 107,823 shares of the company’s stock, valued at approximately $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The stock was sold at an average price of $5.05, for a total value of $10,706.00.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Price Performance

OM stock opened at $5.11 on Friday. The company’s 50-day moving average price is $4.35 and its two-hundred day moving average price is $10.89. The firm has a market cap of $92.75 million, a P/E ratio of -0.39 and a beta of 2.07. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. Outset Medical, Inc. has a 12 month low of $3.10 and a 12 month high of $21.98.

Institutional Trading of Outset Medical

Several institutional investors have recently modified their holdings of OM. Assenagon Asset Management S.A. acquired a new position in Outset Medical during the 3rd quarter worth about $5,324,000. Geode Capital Management LLC increased its stake in shares of Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after buying an additional 376,196 shares during the period. Pura Vida Investments LLC raised its position in shares of Outset Medical by 8,482.4% during the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after acquiring an additional 424,120 shares during the last quarter. Ensign Peak Advisors Inc lifted its stake in shares of Outset Medical by 272.4% in the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock worth $6,042,000 after acquiring an additional 230,065 shares during the period. Finally, Alyeska Investment Group L.P. lifted its stake in shares of Outset Medical by 10.2% in the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after acquiring an additional 150,000 shares during the period.

Analysts Set New Price Targets

OM has been the subject of a number of research analyst reports. Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. Stifel Nicolaus lowered their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 7th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research note on Wednesday, December 17th. Finally, BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Outset Medical currently has an average rating of “Moderate Buy” and an average target price of $10.67.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.